A similar scenario can be drawn for the mutant NF1 clones observed in HMA nonresponder cases, where MEK inhibitors, already studied in AML (50), could be also assessed alone or in combination with splicing inhibitors in clones with co-occurrent mutations for both pathways. This evidence concerns the gene NF1 and acute myeloid leukemia.